EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

FGFC1 overcomes Ara-C resistance in acute myeloid leukemia by inducing apoptosis and pyroptosis

Xiaohui Hu, Zhijian Li, Rui Zhou, Bing Zhang, Ruoxian Wang, Tongtong Li, Jiangcheng Chang, Wenhui Wu, Ning Liu

Frontiers in Pharmacology · 14.08.2025 · 16

DOI: 10.3389/fphar.2025.1584376 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 14.08.2025. Verfasst von Xiaohui Hu und 8 weiteren Autor:innen. Beteiligte Einrichtung: International Research Centre for Food and Health, College of Food Science and Technology, Shanghai Ocean University, Shanghai, China. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Acute myeloid leukemia (AML) is a hematologic malignancy with a high mortality rate and poor prognosis, largely attributed to the emergence of chemotherapy resistance. Cytarabine (Ara-C), the cornerstone chemotherapeutic agent for AML, faces significant challenges due to the development of resistance, creating an urgent need for novel therapeutic strategies. Pyroptosis as a new form of programmed cell death has emerged as a potential therapeutic target in tumor treatment. However, its role in overcoming Ara-C resistance in AML by modulating pyroptosis remains unexplored. FGFC1 (Fungi fibrinolytic compound 1) a natural compound derived from Stachybotrys longispora FG216, has previously been shown to have high efficacy against erlotinib-resistant non-small cell lung cancer, yet its effects on AML are unknown. This study demonstrated that FGFC1 overcame Ara-C resistance in AML by inducing apoptosis and pyroptosis. Mechanistically, FGFC1 induced mitochondrial dysfunction and the accumulation of intracellular reactive oxygen species (ROS), leading to the release of cytochrome c (Cyto-C), which activated Caspase-3 and triggered both apoptosis and pyroptosis. This process was driven by inhibition of the PI3K/Akt/mTOR signaling cascade, ultimately suppressing the growth of AML Ara-C-resistant cells. These findings highlight the potential of FGFC1 to overcome Ara-C resistance in AML, providing a promising therapeutic strategy for drug-resistant AML and supporting the broader application of marine-derived small molecules in cancer therapy.

Schlagwörter

Stichwörter der Autor:innen

FGFC1GSDMEacute myeloid leukemia (AML)apoptosis and pyroptosiscytarabine (Ara-C) resistance

Autor:innen und Institutionen

  • International Research Centre for Food and Health, College of Food Science and Technology, Shanghai Ocean University, Shanghai, China.
  • Marine Biomedical Science and Technology Innovation Platform of Lin-gang Special Area, Shanghai, China.
  • Department of Chemistry, College of Food Science and Technology, Shanghai Ocean University, Shanghai, China.
  • Shanghai Engineering Research Center of Aquatic-Product Processing and Preservation, Shanghai, China.

Zitieren

APA

Hu, X., Li, Z., Zhou, R., Zhang, B., Wang, R., Li, T., Chang, J., Wu, W., & Liu, N. (2025). FGFC1 overcomes Ara-C resistance in acute myeloid leukemia by inducing apoptosis and pyroptosis. Frontiers in Pharmacology, 16. https://doi.org/10.3389/fphar.2025.1584376

Vancouver

Hu X, Li Z, Zhou R, Zhang B, Wang R, Li T, et al. FGFC1 overcomes Ara-C resistance in acute myeloid leukemia by inducing apoptosis and pyroptosis. Frontiers in Pharmacology. 2025;16. doi:10.3389/fphar.2025.1584376

BibTeX
@article{Hu2025,
  author = {Hu, Xiaohui and Li, Zhijian and Zhou, Rui and Zhang, Bing and Wang, Ruoxian and Li, Tongtong and Chang, Jiangcheng and Wu, Wenhui and Liu, Ning},
  title = {FGFC1 overcomes Ara-C resistance in acute myeloid leukemia by inducing apoptosis and pyroptosis},
  journal = {Frontiers in Pharmacology},
  year = {2025},
  volume = {16},
  doi = {10.3389/fphar.2025.1584376}
}
Kostenlos starten →